Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk factors: Individual assessment of CKD risk in HIV-positive patients.

Literature DB >> 25963593

Risk factors: Individual assessment of CKD risk in HIV-positive patients.

Rebecca Scherzer¹, Michael G Shlipak¹.

Abstract

Entities: Disease Species

Mesh：

Substances：
Anti-HIV Agents

Year: 2015 PMID： 25963593 DOI： 10.1038/nrneph.2015.75

Source DB: PubMed Journal: Nat Rev Nephrol ISSN： 1759-5061 Impact factor: 28.314

× No keyword cloud information.

10 in total

1. Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors: Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal: AIDS Date: 2012-04-24 Impact factor: 4.177

2. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.

Authors: Meghan E Sise; Jamie S Hirsch; Pietro A Canetta; Leal Herlitz; Sumit Mohan
Journal: AIDS Date: 2015-05-15 Impact factor: 4.177

3. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.

Authors: Vasantha Jotwani; Yongmei Li; Carl Grunfeld; Andy I Choi; Michael G Shlipak
Journal: Am J Kidney Dis Date: 2011-12-28 Impact factor: 8.860

4. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.

Authors: Andy Choi; Rebecca Scherzer; Peter Bacchetti; Phyllis C Tien; Michael S Saag; Cynthia L Gibert; Lynda A Szczech; Carl Grunfeld; Michael G Shlipak
Journal: Am J Kidney Dis Date: 2010-08-14 Impact factor: 8.860

Review 5. Single-tablet regimens in HIV: does it really make a difference?

Authors: Isabel Aldir; Ana Horta; Margarida Serrado
Journal: Curr Med Res Opin Date: 2013-10-04 Impact factor: 2.580

6. Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).

Authors: Ikwo Oboho; Alison G Abraham; Lorie Benning; Kathryn Anastos; Anjali Sharma; Mary Young; Pamela Burian; Monica Gandhi; Mardge Cohen; Lynda Szczech
Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731

Review 7. Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making.

Authors: Yishen Wang; Beata Bajorek
Journal: Ther Adv Drug Saf Date: 2014-02

8. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.

Authors: Takeshi Nishijima; Takuro Shimbo; Hirokazu Komatsu; Misao Takano; Junko Tanuma; Kunihisa Tsukada; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Shinichi Oka
Journal: J Infect Chemother Date: 2013-03-07 Impact factor: 2.211

9. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.

Authors: Rebecca Scherzer; Monica Gandhi; Michelle M Estrella; Phyllis C Tien; Steven G Deeks; Carl Grunfeld; Carmen A Peralta; Michael G Shlipak
Journal: AIDS Date: 2014-06-01 Impact factor: 4.177

10. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Authors: Amanda Mocroft; Jens D Lundgren; Michael Ross; Matthew Law; Peter Reiss; Ole Kirk; Colette Smith; Deborah Wentworth; Jacqueline Neuhaus; Christoph A Fux; Olivier Moranne; Phillipe Morlat; Margaret A Johnson; Lene Ryom
Journal: PLoS Med Date: 2015-03-31 Impact factor: 11.069

10 in total

5 in total

Risk factors: Individual assessment of CKD risk in HIV-positive patients.

1. Association of tenofovir exposure with kidney disease risk in HIV infection.

2. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.

3. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.

4. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.

Review 5. Single-tablet regimens in HIV: does it really make a difference?

6. Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).

Review 7. Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making.

8. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.

9. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.

10. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Review 1. Hepatitis C Virus Infection in Chronic Kidney Disease.

Review 2. A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

Review 3. HIV and kidney diseases: 35 years of history and consequences.

Review 4. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.

Review 5. CNS Neurotoxicity of Antiretrovirals.